reports
- Rune Majlund Dahl
Coloplast (Hold, TP: DKK770.00) - Expecting another weak quarter
We expect another soft quarter (7.8% organic revenue growth YOY and a 27.5% EBIT margin), before then improving. We look for unchanged 2024/25 guidance of 8–9% organic sales growth and a c28% EBIT margin before special items. We have cut our 2024/25–2026/27e EPS by 2.8% on average and believe returning to a 30%+ EBIT margin hinges on external factors. We reiterate our HOLD, but have cut our target price to DKK770 (850).
Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference...
Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the e...
- Rune Majlund Dahl
Coloplast (Hold, TP: DKK850.00) - 2024/25 likely back-end loaded
The Q1 headline results were broadly in line with our forecasts and consensus. We view 2024/25 as back-end loaded and expect a pick-up in organic growth and margins over the coming quarters. The company maintained its 2024/25 guidance for 8–9% organic sales growth and a c28% EBIT margin before special items. We reiterate our HOLD and DKK850 target price.
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Allocation of Share Options
Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address: Details of the person discharging managerial responsibi...
- Marc Lavaud
- Martin Marandon-Carlhian
- Stephane Houri
- Marc Lavaud
- Martin Marandon-Carlhian
- Stephane Houri
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Interim Financial Report, Q1 2024/25
Coloplast A/S - Interim Financial Report, Q1 2024/25 2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 7%, Voice and Respiratory Care 11%, Advanced Wound Care 12% and Interventional Urology 1%.Growth in Chronic Care was driven by solid contributions from Europe and the US, while gr...
Coloplast A/S - Regnskabsmeddelelse, Q1 2024/25
Coloplast A/S - Regnskabsmeddelelse, Q1 2024/25 2024/25 Delårsrapport, 1. kvartal 2024/25 1. oktober 2024 – 31. december 2024 Coloplast leverede en organisk vækst på 8% og en overskudsgrad1 på 27% i 1. kvartal, som forventet. Den rapporterede omsætning målt i danske kroner steg 6%, negativt påvirket af frasalget af hudplejeforretningen og valutaudvikling. Den organiske vækst pr. forretningsområde var 7% i Stomi, 7% i Kontinens, 11% i Stemme og Respiratorisk Pleje, 12% i Avanceret Sårpleje og 1% i Urologi.Væksten i den kroniske forretning var drevet af solide bidrag fra Europa og USA, ...
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference...
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction) Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation)In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour befor...
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference...
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET Tuesday, 4 February 2025 at 10.00 - 11.00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and afte...
- Rune Majlund Dahl
Coloplast (Hold, TP: DKK850.00) - Q1 likely below full-year guidance
We forecast Q1 results below the full-year guidance, with organic growth of 7.5% and an EBIT before special items margin of 27.0%, but expect improvements in subsequent quarters. We look for unchanged guidance of 8–9% organic growth and a c28% EBIT margin before special items. We believe returning to 30%+ EBIT margins hinges on external factors. We reiterate our HOLD but have cut our target price to DKK850 (930).
- ABGSC Healthcare Research
- Morten Larsen
Coloplast AS: 1 director
A director at Coloplast AS bought 23,700 shares at 845.850DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2024
Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2024 I dag, den 5. december 2024, har Coloplast A/S afholdt ordinær generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2023/24 blev godkendt.Forslag om udbetaling af ordinært udbytte på 17,00 kr. pr. aktie á nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie á nominelt 1 kr. udbetalt i forbindelse med halvårsresultatet, vil der således være udbetalt udbytte for regnskabsåret 2023/24 på samlet 22,00 kr. pr. aktie á nominelt 1 kr.Vederlagsrapporten for regnskabsåret 2023/...
Coloplast A/S - Decisions at the Annual General Meeting 2024
Coloplast A/S - Decisions at the Annual General Meeting 2024 Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per share of nominally DKK 1.The remuneratio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.